Atlas Trials

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Clinical trial NCT04829604 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04829604
Sponsor
Ambrx, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HER2 Positive Metastatic Breast Cancer
Start date
2021-10-26
Primary completion
2026-12-01
Enrollment
72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.